Wednesday, July 8, 2026

pharma · Asthma · Osteoarthritis · AMRX

Amneal Pharma Europe

Amneal Pharma Europe is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker AMRX. Primary therapeutic focus areas include Asthma, Osteoarthritis, Schizophrenia, Open-angle Glaucoma, Pa

400 Crossing Boulevard, Bridgewater, New Jersey 08807, US HQ
2002 Founded
7,179 Employees
Public company Type
AMRX · NYSE Ticker
Company details
Status
Public
HQ
400 Crossing Boulevard, Bridgewater, New Jersey 08807, US
Founded
2002
Employees
7,179
Programs
15
Drugs
210
Patents
32
Clinical program

AM-PHN-004

Phase 3 · small molecule · Uncomplicated Urinary Tract Infections

AM-PHN-004 for Uncomplicated Urinary Tract Infections is a Phase 3 program (small_molecule) at Amneal Pharma Europe Ltd with 1 ClinicalTrials.gov record(s).

← All Amneal Pharma Europe Ltd projects Phase 3 small molecule completed

Internal code AM-PHN-004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Amneal Pharma Europe Ltd
Phase
Phase 3
Modality
small_molecule
Indication
Uncomplicated Urinary Tract Infections
Status
completed
Trials
1